CC 95266
Alternative Names: BMS-986393; CC-95266Latest Information Update: 12 Apr 2024
At a glance
- Originator Juno Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Multiple myeloma
Most Recent Events
- 21 Mar 2024 Phase-II clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV) (NCT06297226)
- 16 Feb 2024 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater, Combination therapy) in USA (IV) (NCT06121843)
- 11 Dec 2023 Juno Therapeutics plans a phase II trial in Multiple myeloma (second-line therapy or greater) in the first half of 2024